2017 International Congress Archives - Page 51 of 155

Wearable gait sensors to measure degenerative cerebellar ataxia

R. Sakakibara, K. Terayama, O. Akihiro, H. Haruta, T. Akiba, F. Tateno, M. Kishi, Y. Tsuyusaki, Y. Aiba, T. Ogata (Sakura, Japan)
Wearable motion quantification and electronic diaries for long-term monitoring of Parkinson’s disease

A. Hadley, E. Mendoza, N. Mennucci, C. Zimmerman, J. Giuffrida, Z. Mari, M. Burack, I. Itin, F. Revilla, D. Heldman (Cleveland, OH, USA)
Wearable sensor-based therapy titration for Parkinson’s Disease

R. Schmidt, D. Heldman, A. Hadley, D. Riley (Cleveland, OH, USA)
Wearing Off Frequency in Different Hoehn-Yahr Stages in Parkinson’s Disease

H. Cotur Levent, E. Bayram, M. Akbostanci (Ankara, Turkey)
Weight Changes in STN and GPi Deep Brain Stimulation: Long Term Follow up

S. Shah, L. Almeida, A. Patterson, J. Hilliard, A. Wagle Shukla, K. Foote, M. Okun, D. Martinez-Ramirez, P. Zeilman (Gainesville, FL, USA)
Weight loss in Parkinson’s disease (PD)

K. Khalid, D. Linsky, H. Khan, S. Pradhan, A. Chatterjee (Reading, United Kingdom)
What do patients with Parkinson’s disease see in their hallucinations? Classification of hallucinations which are seen in Parkinson’s Disease; Single Center Experience

A. Acarer, S. Ciftci, Z. Colakoglu (Izmir, Turkey)
What does the severity of hemifacial spasm mean to us?

J. Youn, J.W. Cho (Seoul, Republic of Korea)
What impacts relationship satisfaction in Parkinsonian dementias?

S. Vatter, K. McDonald, S. McCormick, I. Leroi (Manchester, United Kingdom)
What strategies do Parkinson’s disease patients use for getting out of bed in the early morning? Preliminary results from home video analysis of 22 patients.

J. Sringean, C. Anan, R. Bhidayasiri (Bangkok, Thailand)
Where Are The Main Lesions That Cause Orthostatic Hypotension In Parkinson’s Disease ?

R. Sengoku, M. Shibukawa, M. Yamazaki, K. Eguchi, M. Higashihara, D. Kaneda, Y. Nishina, K. Kanemaru, S. Murayama (Tokyo, Japan)
Which clinical features predict progressive supranuclear palsy pathology? A clinicopathological study on 437 autopsy cases and a literature review

G. Respondek, C. Kurz, T. Arzberger, E. Gelpi, D. Irwin, W. Meissner, A. Pantelyat, A. Rajput, J. Van Swieten, C. Troakes, K. Josephs, A. Lang, U. Mueller, C. Nilsson, Y. Bordelon, J.-C. Corvol, A. Boxer, L. Golbe, I. Litvan, M. Stamelou, G. Hoeglinger (Munich, Germany, Germany)
Which factors predict patient satisfaction with botulinum toxin treatment for cervical dystonia?

C. Colosimo, V. Misra, D. Charles, T.M. Chung, S. Om, P. Maisonobe (Terni, Italy)
Which self-report motor experiences of daily living best predict objective motor function in patients with Parkinson’s disease?

S. Anderson, J. Goldman, S. Luo, A. Negron, C. Goetz, G. Stebbins (Chicago, IL, USA)
White matter lesions and peripheral vessel reactivity in dementia with Lewy bodies

A. Chimagomedova, E. Vasenina, O. Levin (Moscow, Russian Federation)
White matter microstructural damage as predictor of cognitive decline in Parkinson’s disease

T. Stojkovic, E. Stefanova, F. Agosta, S. Galantucci, I. Stankovic, V. Markovic, E. Canu, M. Copetti, M. Filippi, V. Kostic (Belgrade, Serbia)
White Matter Microstructural Features of Motor Subtypes in De Novo, Drug Naïve Parkinson’s Disease Patient

M.-C. Wen, H. Heng, Z. Lu, Z. Xu, L.L. Chan, E.K. Tan, L. Tan (Singapore, Singapore)
Whole Exome Sequencing (WES) identifies a TUBB4A Mutation in two Saudi siblings with hypomyelinating leukodystrophy associated with atrophy of basal ganglia and cerebellum.

Z. Aldaajani, E.-S. Ali (Dhahran, Saudi Arabia)
Whole exome sequencing in essential tremor.

I. Alfradique-Dunham, L. Robak, A. Kaw, O. Fagbongbe, Z. Coban Akdemir, E. Young, J. Lupski, J. Jankovic, J. Shulman (Houston, TX, USA)
WILSON’S DISEASE: A Mongolian case

U. Dashdorj, S. Jambal (Ulaanbaatar 51, Mongolia)
Writing training enhances neural connectivity in Parkinson’s patients with micrographia

E. Nackaerts, J. Michely, E. Heremans, S. Swinnen, B. Smits-Engelsmans, W. Vandenberghe, C. Grefkes, A. Nieuwboer (Leuven, Belgium)
WTX101 – A Novel Copper Modulating Agent for Wilson Disease Demonstrates Efficacy and Safety in a Phase 2, Multi-Center, Open Label Study

D. Bega, A. Ala, F. Askari, J. Bronstein, A. Czlonkowska, P. Ferenci, D. Nicholl, K.-H. Weiss, M. Schilsky (Chicago, IL, USA)